Figure 1
Figure 1. HLA-G1 allows tumor growth in immunocompetent mice. (A) Schematic representation of experimental procedures. (B) Mice were injected subcutaneously with 10 × 106 M8-pcDNA or M8-HLA-G1 cells and tumor growth was monitored at indicated time points. Data represent the means ± SD from 1 representative experiment with 3 mice in each group. Insert shows cell-surface expression of HLA-G1 by the M8-pcDNA and M8-HLA-G1 cell lines and the isotype control. (C) Photographs of subcutaneous tumors 3 days after injection of tumor cells. (D) Expression of HLA-G and melanoma antigens at the tumor site at day 14 (d14). (E) M8-HLA-G1 cells were pretreated with the 87G Ab (M8-HLA-G1 + anti-HLA-G) or the isotype control (M8-HLA-G1 + control Ab) before subcutaneous injection into Balb/c mice, and tumor growth was monitored at the indicated time points. Data represent the means ± SD from 1 representative experiment with 3 mice in each group.

HLA-G1 allows tumor growth in immunocompetent mice. (A) Schematic representation of experimental procedures. (B) Mice were injected subcutaneously with 10 × 106 M8-pcDNA or M8-HLA-G1 cells and tumor growth was monitored at indicated time points. Data represent the means ± SD from 1 representative experiment with 3 mice in each group. Insert shows cell-surface expression of HLA-G1 by the M8-pcDNA and M8-HLA-G1 cell lines and the isotype control. (C) Photographs of subcutaneous tumors 3 days after injection of tumor cells. (D) Expression of HLA-G and melanoma antigens at the tumor site at day 14 (d14). (E) M8-HLA-G1 cells were pretreated with the 87G Ab (M8-HLA-G1 + anti-HLA-G) or the isotype control (M8-HLA-G1 + control Ab) before subcutaneous injection into Balb/c mice, and tumor growth was monitored at the indicated time points. Data represent the means ± SD from 1 representative experiment with 3 mice in each group.

Close Modal

or Create an Account

Close Modal
Close Modal